Grifols SA Posts Strong 2024 Results, Exceeding Guidance
Ticker: GIKLY · Form: 6-K · Filed: Feb 26, 2025 · CIK: 1438569
| Field | Detail |
|---|---|
| Company | Grifols SA (GIKLY) |
| Form Type | 6-K |
| Filed Date | Feb 26, 2025 |
| Risk Level | low |
| Sentiment | bullish |
Sentiment: bullish
Topics: earnings, revenue-growth, financial-results
TL;DR
Grifols crushed 2024 guidance with EUR 7.2B revenue, up 10.3%!
AI Summary
Grifols SA reported strong Q4 and full-year 2024 results, with revenue reaching EUR 1,976 million in Q4, a 13.6% increase at constant currency, driven by Biopharma's 15.1% growth. For the full year 2024, revenue was EUR 7,212 million, up 10.3% at constant currency, exceeding guidance for both revenue and free cash flow.
Why It Matters
The company's performance exceeding financial guidance suggests robust operational execution and market demand for its products, potentially leading to increased investor confidence.
Risk Assessment
Risk Level: low — This filing is a routine earnings report and does not contain any significant negative news or unexpected events.
Key Numbers
- EUR 7,212 million — FY24 Revenue (Exceeded guidance for the full year.)
- 10.3% — FY24 Revenue Growth (cc) (Demonstrates strong top-line performance.)
- EUR 1,976 million — Q4 Revenue (Significant growth driven by Biopharma.)
- 13.6% — Q4 Revenue Growth (cc) (Highlights strong quarterly performance.)
Key Players & Entities
- Grifols SA (company) — Registrant
- EUR 1,976 million (dollar_amount) — Q4 Revenue
- 13.6% (dollar_amount) — Q4 Revenue growth at constant currency
- 15.1% (dollar_amount) — Biopharma Q4 growth at constant currency
- EUR 7,212 million (dollar_amount) — FY24 Revenue
- 10.3% (dollar_amount) — FY24 Revenue growth at constant currency
FAQ
What was Grifols' total revenue for the fourth quarter of 2024?
Grifols' revenue reached EUR 1,976 million in the fourth quarter of 2024.
What was the year-over-year revenue growth for Grifols in FY24?
Grifols reported a 10.3% increase in revenue at constant currency for FY24, reaching EUR 7,212 million.
Which segment was the primary driver of Q4 revenue growth?
Biopharma's growth of 15.1% at constant currency was the primary driver of the Q4 revenue increase.
Did Grifols meet its financial guidance for 2024?
Yes, Grifols delivered a strong 2024, exceeding guidance on both revenue and free cash flow.
What is the filing date for this Form 6-K?
This Form 6-K was filed on February 26, 2025.
Filing Details
This Form 6-K (Form 6-K) was filed with the SEC on February 26, 2025 regarding Grifols SA (GIKLY).